Answers are grounded in this paper and cite their sources.
Demonstrates that gemfibrozil lowers VLDL and shifts lipoprotein subfractions in hypertriglyceridaemia, indicating lipoprotein lipase activation and attenuated VLDL-to-LDL transfer over time.
Serum lipoproteins and apolipoproteins were studied in 14 hypertriglyceridaemic (HTG) patients during a 24-week period of treatment with gemfibrozil, and after a 6-week washout period. A marked decrease in very low density lipoprotein (VLDL) cholesterol and triglyceride was observed. There was an increase in high density lipoprotein (HDL) cholesterol, particularly the HDL3 component. A slight increase in low density lipoprotein (LDL) cholesterol was observed after 12 weeks, but this had almost disappeared after 24 weeks. The treatment resulted in an increase in serum apolipoprotein A-II levels and a reduction in serum apo C-III and apo E. VLDL subfractionation by density gradient centrifugation in four subfractions of decreasing size (A, B, C and D) showed a predominant reduction of the large subfractions A, B and C, while the decrease in VLDL-D was less marked. Percentage changes from the baseline level of VLDL-A and VLDL-D cholesterol were found to be inversely correlated with percentage changes in HDL and LDL cholesterol, respectively. This might reflect a transfer of cholesterol from VLDL-A to HDL, and from VLDL-D to LDL. The above data suggest fibrate-induced stimulation of lipoprotein lipase, and indicate that the enhanced transfer of cholesterol from VLDL to LDL, induced by fibrates in HTG patients, is less pronounced after a prolonged period of treatment.
No takes yet. Share an insight, caveat, or question.
Pauciullo et al. (1990) studied Primary hypertriglyceridaemia (n=14). Gemfibrozil was evaluated on Changes in serum lipoproteins, apolipoproteins, and VLDL subfractions.
Synapse has enriched 10 related papers. Consider them for comparative context: